Hidradenitis Suppurativa: Rapid Evidence Review

Area of Science:

• Dermatology
• Chronic Inflammatory Diseases

Background:

• Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition affecting hair follicles, primarily in intertriginous areas.
• Onset typically occurs between 18 and 39 years of age, with higher incidence in females and Black individuals.
• Risk factors include family history, smoking, obesity, and associations with comorbidities like diabetes mellitus and Crohn disease.

Purpose of the Study:

• To provide a comprehensive overview of hidradenitis suppurativa (HS).
• To detail the clinical presentation, risk factors, and associated conditions of HS.
• To outline current and emerging treatment strategies for HS.

Main Methods:

• Literature review of hidradenitis suppurativa (HS) epidemiology, clinical features, and treatment modalities.
• Analysis of therapeutic options ranging from conservative measures to advanced pharmacological and surgical interventions.
• Emphasis on the impact of HS on quality of life and the need for psychological screening.

Main Results:

• HS presents a spectrum from mild nodules to severe scarring, significantly impacting quality of life and potentially indicating depression.
• Mild HS may respond to topical clindamycin; moderate cases benefit from oral antibiotics (e.g., tetracyclines) and topical treatments.
• Moderate to severe HS shows efficacy with adalimumab (a TNF-alpha inhibitor); surgical options like debridement and wide excision are crucial for definitive management.

Conclusions:

• Hidradenitis suppurativa (HS) requires a multi-faceted treatment approach tailored to disease severity.
• Lifestyle modifications (weight loss, smoking cessation) are foundational.
• Pharmacological and surgical interventions, including novel biologics and surgical procedures, are essential for managing moderate to severe HS.